| 產(chǎn)品編號 | bs-20395R |
| 英文名稱 | Thrombomodulin Rabbit pAb |
| 中文名稱 | 血栓調(diào)節(jié)蛋白抗體 |
| 別 名 | CD 141; CD141; CD141 antigen; Fetomodulin; THBD; THRM; TM; AHUS 6; AHUS6; BDCA 3; BDCA3; THPH12; TRBM_HUMAN. |
 |
Specific References (2) | bs-20395R has been referenced in 2 publications.
[IF=4.57] Daisuke Noguchi. et al. The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia‐reperfusion injury in mice. 2020 Oct 27 WB ; Mouse.
[IF=1.26] Zhao et al. Unfractionated heparin protects the protein C system against lipopolysaccharide-induced damagein vivoandin vitro. (2017) Exp.Ther.Med. 14:5515-5522 WB ; Human.
|
| 研究領(lǐng)域 | 心血管 細胞生物 神經(jīng)生物學(xué) 血管內(nèi)皮細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號 | |
| 交叉反應(yīng) | Human (predicted: Mouse,Sheep,Cow,Dog) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 61 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Thrombomodulin: 21-120/575 <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | Preservative: 0.02% Proclin300, Constituents: 1% BSA, 0.01M PBS, pH7.4. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Thrombomodulin, TM is cell surface glycoprotein; plays an important role in the protein C anticoagulant pathway. It located in a vein, artery and capillary endothelial cells on the surface of plasma membrane protein. It is generally believed: TM vascular endothelial injury is an important parameter is the thrombin receptor, known in a variety of normal human tissues, can also be expressed in many tumors, TM may be similar to the E-cadherin,and is a lectin Like activity of a new class of members of the cell adhesion molecules. CD141/Thrombomodulin is an exclusively endothelial cell surface glycoprotein that forms a 1:1 complex with thrombin. Binding of thrombin to this high-affinity receptor alters its specificity toward several substrates. The complex activates protein C approximately 1000 times faster than thrombin alone. Activated protein C degrades clotting factors V and VIII; thus, thrombomodulin converts thrombin into a physiologic anticoagulant. Thrombomodulin is also found in the circulatory and urinary systems, the physiologic significance of this is obscure. Function: Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated. Subcellular Location: Membrane; Single-pass type I membrane protein. Tissue Specificity: Endothelial cells are unique in synthesizing thrombomodulin. Post-translational modifications: N-glycosylated. The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains. DISEASE: Defects in THBD are the cause of thrombophilia due to thrombomodulin defect (THPH12) [MIM:614486]. A hemostatic disorder characterized by a tendency to thrombosis. Defects in THBD are a cause of susceptibility to hemolytic uremic syndrome atypical type 6 (AHUS6) [MIM:612926]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Similarity: Contains 1 C-type lectin domain. Contains 6 EGF-like domains. SWISS: P07204 Gene ID: 7056 Database links: Entrez Gene: 7056 Human Omim: 188040 Human SwissProt: P07204 Human Unigene: 2030 Human 血栓調(diào)節(jié)蛋白(thrombomodulin,TM)是一種分布于靜脈、動脈和毛細血管內(nèi)皮細胞表面的質(zhì)膜蛋白。 一般認(rèn)為：TM是血管內(nèi)皮損傷的重要參數(shù)，也是凝血酶的受體，已知在人類多種正常組織中表達，亦可表達于許多腫瘤組織，TM可能類似于鈣粘蛋白，是具有凝集素樣活性的新一類細胞粘附分子的成員。TM是血管內(nèi)皮細胞膜上的凝血酶受體之一。與凝血酶結(jié)合后可降低凝血酶的凝血活性，而加強其激活蛋白C的活性。由于被激活的蛋白C具有抗凝作用，因此，TM是使凝血酶由促凝轉(zhuǎn)向抗凝的重要的血管內(nèi)凝血抑制因子。 |
| 產(chǎn)品圖片 |
Sample:
Lane 1: A431 (Human) Cell Lysate at 30 ug
Lane 2: Huvec (Human) Cell Lysate at 30 ug
Lane 3: A549 (Human) Cell Lysate at 30 ug
Primary: Anti-Thrombomodulin (bs-20395R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 61 kD
Observed band size: 120 kD
|
